Wealth Enhancement Advisory Services
LAB icon

Wealth Enhancement Advisory Services’s Standard BioTools LAB Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.7K Buy
42,090
+11,631
+38% +$11K ﹤0.01% 3955
2026
Q1 		$27.7K Buy
30,459
+13,535
+80% +$16.4K ﹤0.01% 3482
2025
Q4 		$21.5K Sell
16,924
-3,820
-18% -$5.13K ﹤0.01% 3584
2025
Q3 		$27K Buy
20,744
+388
+2% +$508 ﹤0.01% 3488
2025
Q2 		$27.5K Buy
20,356
+106
+0.5% +$118 ﹤0.01% 3275
2025
Q1 		$21.9K Buy
+20,250
New +$28.4K ﹤0.01% 2910
2024
Q4 		– Sell
-10,197
Closed -$19.7K – 3048
2024
Q3 		$19.7K Buy
+10,197
New +$20K ﹤0.01% 2667

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Wealth Enhancement Advisory Services's LAB Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Standard BioTools (LAB) stake by 38% in Q2 2026, buying an estimated $11K and bringing the position to 42,090 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3955.

Wealth Enhancement Advisory Services first reported a position in LAB in Q3 2024 and has held it in 7 quarters since. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Wealth Enhancement Advisory Services held 42,090 shares of Standard BioTools worth $38.7K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 11,631 Standard BioTools shares in Q2 2026, an estimated $11K.
  • Standard BioTools made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3955 holding.
  • Wealth Enhancement Advisory Services first reported a position in Standard BioTools in Q3 2024 and has held it in 7 quarters since.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.